The maker of the EpiPen could be about to get a huge run for its money
CNBC Screenshot
From the blog post:
We stand ready to quickly review additional applications that come to us from manufacturers, especially applications for generic versions. To speed along the process, our Office of Generic Drugs prioritizes and expedites our review of applications for first generics, making sure that the first applicants to make a generic are moved to the head of the queue and given priority review.
The EpiPen, which is an epinephrine auto-injector that treats people who are going through anaphylactic shock due to an allergic reaction, has been the subject of public outcry.
The drug's price has increased by about 500% in less than a decade to $608. And while the CEO of Mylan, the company that makes the pen, has promised to provide assistance for patients in need and create a generic pen, that hasn't satisfied consumers.
And it seems it hasn't satisfied the FDA either.
In the post, the agency said it has already approved four epinephrine auto-injectors.
"To help development, we built a roadmap that will get these products on the market faster. In June 2013, the agency provided technical information for industry about designing and testing auto-injectors. In February, the FDA provided industry with draft guidance on how to determine if patients can effectively use the new devices," it said.
So it looks like Mylan's going to have a run for its money.
- Go Digit IPO allotment – How to check allotment, GMP, listing date and more
- 10 breathtaking valleys to visit in India in 2024
- Following Rohit Sharma's accusation, IPL broadcaster Star Sports denies airing audio of any personal conversation
- WATCH: Massive comet fragment blazes up in beautiful blue flames over Portugal and Spain
- 10 dry fruits for improved vision
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market